LCZ696 (Sacubitril/Valsartan): Can We Predict Who Will Benefit?
Journal of the American College of Cardiology（2015）
摘要
The recent U.S. Food and Drug Administration approval of LCZ696, a combination of sacubitril and valsartan, has generated palpable excitement among heart failure (HF) clinicians [(1)][1]. Several lines of evidence have pointed to the potential benefits of drugs combining renin-angiotensin-
更多查看译文
关键词
neprilysn inhibition,sacubitril/valsartan
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要